Specifically, the study revealed elevated concentrations of deoxycholic acid (DCA), which acts as an antagonist of FXR, and decreased levels of the agonistic bile acid chenodeoxycholic acid (CDCA) in NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.